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Articles
Effect of a novel vital sign device on maternal mortality and 
morbidity in low-resource settings: a pragmatic, 
stepped-wedge, cluster-randomised controlled trial
Nicola Vousden, Elodie Lawley, Hannah L Nathan, Paul T Seed, Muchabayiwa Francis Gidiri, Shivaprasad Goudar, Jane Sandall, Lucy C Chappell*, 
Andrew H Shennan*, on behalf of the CRADLE Trial Collaborative Group†
Summary
Background In 2015, an estimated 303 000 women died in pregnancy and childbirth. Obstetric haemorrhage, sepsis, 
and hypertensive disorders of pregnancy account for more than 50% of maternal deaths worldwide. There are 
effective treatments for these pregnancy complications, but they require early detection by measurement of vital 
signs and timely administration to save lives. The primary aim of this trial was to determine whether implementation 
of the CRADLE Vital Sign Alert and an education package into community and facility maternity care in low-
resource settings could reduce a composite of all-cause maternal mortality or major morbidity (eclampsia and 
hysterectomy).
Methods We did a pragmatic, stepped-wedge, cluster-randomised controlled trial in ten clusters across Africa, India, 
and Haiti, introducing the device into routine maternity care. Each cluster contained at least one secondary or 
tertiary hospital and their main referral facilities. Clusters crossed over from existing routine care to the CRADLE 
intervention in one of nine steps at 2-monthly intervals, with CRADLE devices replacing existing equipment at the 
randomly allocated timepoint. A computer-generated randomly allocated sequence determined the order in which 
the clusters received the intervention. Because of the nature of the intervention, this trial was not masked. Data 
were gathered monthly, with 20 time periods of 1 month. The primary composite outcome was at least one of 
eclampsia, emergency hysterectomy, and maternal death. This study is registered with the ISRCTN registry, 
number ISRCTN41244132.
Findings Between April 1, 2016, and Nov 30, 2017, among 536 223 deliveries, the primary outcome occurred in 
4067 women, with 998 maternal deaths, 2692 eclampsia cases, and 681 hysterectomies. There was an 8% decrease in 
the primary outcome from 79·4 per 10 000 deliveries pre-intervention to 72·8 per 10 000 deliveries post-intervention 
(odds ratio [OR] 0·92, 95% CI 0·86–0·97; p=0·0056). After planned adjustments for variation in event rates between 
and within clusters over time, the unexpected degree of variability meant we were unable to judge the benefit or harms 
of the intervention (OR 1·22, 95% CI 0·73–2·06; p=0·45). 
Interpretation There was an absolute 8% reduction in primary outcome during the trial, with no change in resources 
or staffing, but this reduction could not be directly attributed to the intervention due to variability. We encountered 
unanticipated methodological challenges with this trial design, which can provide valuable learning for future 
research and inform the trial design of future international stepped-wedge trials.
Funding Newton Fund Global Research Programme: UK Medical Research Council; Department of Biotechnology, 
Ministry of Science & Technology, Government of India; and UK Department of International Development. 
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Maternal mortality remains a challenge worldwide, 
especially in low-resource settings, where in 2015, an 
estimated 303 000 women died from complications of 
pregnancy and childbirth.1 The leading direct causes of 
maternal mortality are obstetric haemorrhage (27·1%), 
hypertensive disorders (14·0%), sepsis (10·7%), and 
abortion complications (7·9%).2 Simple, evidence-based 
interventions are available for the majority of these 
conditions.3 However, in low-resource settings, delays 
in presenting to care, reaching care, and receiving this 
care all contribute to high maternal mortality.4
Vital sign measurement is the first step in recognising 
women at risk of deterioration (particularly from hyper-
tension, obstetric haemorrhage, and sepsis) and, 
therefore, in initiating treatments that can prevent 
potentially catastrophic maternal and perinatal compli-
cations.5 Early warning systems allow for tracking of vital 
signs to alert health-care providers to abnor malities and 
allow earlier action. They are widely used in high-income 
settings.6 Several studies have found early warning sys-
tems to be beneficial in predicting maternal morbidity 
and mortality, but these studies are generally small and 
retrospective.7–13 Only one prospective, non-randomised 
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study14 has shown that implementation of a paper-based 
early warning system across six pilot hospitals resulted in 
a significant reduction in a compos ite of maternal 
morbidity compared with standard care at non-pilot sites 
in the USA. However, to be effective, early warning 
systems require accurate measurement and docu-
mentation of vital signs followed by calculation of risk 
and appropriate escalation or action. In low-resource 
settings, inadequate access to reliable equipment,15,16 
overstretched staff,17 and poor understanding of preg-
nancy complications and moni toring of vital signs18 can 
potentially lead to delay in identifying and initiating 
treatment in women most at risk.
The CRADLE Vital Sign Alert (VSA) is a semi-
automated device that measures blood pressure and heart 
rate, and calculates shock index (heart rate divided by 
systolic blood pressure). This device has been extensively 
tested and is validated as accurate in pregnant women 
according to international protocols, including in women 
with high and low blood pressure.19–22 Qualitative 
implementation evaluation in low-resource settings has 
determined that it is easy to use, robust, and suitable 
for use by any cadre of health-care provider, even those 
without extensive training, such as community health 
workers.23 Results are displayed digitally and on a traffic 
light early warning system, which indicates abnormal 
vital signs (figure 1).23 This ease of use is important in 
low-resource settings, where routine clinical tasks, such 
as vital signs measurement, are often undertaken by 
health-care workers, students, or volunteers  with 
minimal train ing, and where community health workers 
also play a vital part in maternity care, often being the first 
point of contact and an essential link to clinical services.3,24
The primary aim of the trial was to determine whether 
implementation of the CRADLE VSA and an education 
package into community and facility maternity care in low-
resource settings could reduce a composite of all-cause 
maternal mortality or major morbidity (eclampsia and 
hysterectomy).25 We hypoth esised that this intervention 
would improve the quality of care by increasing the 
number of trained health-care providers (including those 
who informally support routine vital signs measurement, 
such as volunteers) and by providing reliable equipment, 
thus increasing the number of women who receive vital 
signs monitoring and subsequent management of preg-
nancy complications. This trial was preceded by a 6-month 
feasibility study to develop and improve the intervention 
and implementation strategies,26 informed by guidance 
from the UK Medical Research Council for evaluation of 
complex interventions.27
Research in context
Evidence before this study
We searched PubMed for original articles published in English 
before July 1, 2018, with the search terms “maternal OR 
maternity OR pregnancy AND early warning”. We identified 
eight studies (seven undertaken in high-resource settings), 
which examine the predictive capacity of early warning 
systems in pregnancy. No clinical trials or systematic reviews 
were identified. However, it is widely acknowledged that 
delays in recognising and initiating treatment for pregnancy 
complications contribute to maternal mortality. Therefore, 
early warning systems are consistently recommended in 
high-resource settings. In low-resource settings, inadequate 
access to accurate vital signs equipment and trained staff 
further adds to delays in detecting pregnancy complications. 
To our knowledge, no study has yet investigated novel 
solutions that integrate early warning systems into accurate 
equipment to reduce maternal morbidity and mortality in 
low-resource settings.
Added value of this study
This pragmatic, stepped-wedge, cluster-randomised 
controlled trial provides the first assessment of a novel early 
warning system and accurate vital signs device in preventing 
maternal morbidity and mortality in low-resource settings. In 
ten clusters in eight low-income and middle-income 
countries, introduction of the device with an educational 
package into routine maternity care reduced a composite of 
maternal morbidity and mortality, but the variation in event 
rates between and within clusters over time meant this 
reduction could not be attributed to the intervention, despite 
more than 4000 primary outcome events (maternal death, 
eclampsia, or hysterectomy) among a population of more 
than half a million pregnant women. Very few trials of a 
similar size have been done in maternity populations and, to 
our knowledge, none has investigated an early warning 
system.
Implications of all the available evidence
The existing evidence has shown that early warning systems 
might be beneficial in detecting pregnancy complications 
earlier in high-resource settings. This trial has shown a 
reduction in maternal morbidity and mortality during the trial 
period, with no change in resources or staffing. However, the 
unexpected degree of variability within clusters over time and 
between clusters meant that this reduction cannot be 
attributed to the intervention. Evaluation of the intervention 
in individual countries might elucidate mechanisms by which 
it affects outcomes. To our knowledge, this is the first 
stepped-wedge cluster randomised controlled trial across 
multiple countries and continents; the design was chosen 
after careful consideration, including the intention to leave all 
ten sites equipped with vital sign monitoring devices. We 
encountered unanticipated methodological challenges, which 
provide valuable learning for future research and inform the 
trial design of future international stepped-wedge trials.
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Methods
Study design
This pragmatic, stepped-wedge, cluster-randomised con-
trolled trial evaluated the CRADLE VSA intervention in 
routine maternity care in low-resource settings. All 
methods were predefined and published,25 with no impor-
tant methodological changes. Clusters were purposely 
selected to represent a range of low-resource settings. 
Ten clusters across eight countries were identified and 
agreed to participate: Addis Ababa in Ethiopia, Cap Haitien 
in Haiti, Freetown in Sierra Leone, Harare in Zimbabwe, 
Gokak in India, Kampala and Mbale in Uganda, Lusaka 
and Ndola in Zambia, and Zomba plus the Southern 
Region in Malawi. Each cluster comprised at least 
one urban or peri-urban secondary or tertiary health facility 
that provides comprehensive emergency obstetric care 
with multiple peripheral facilities that refer to the central 
hospital.25 Facilities were identified by the local primary 
investigators as the main facilities that refer to the central 
hospital within a feasible geographical area. Community 
health-care providers were included in implementation in 
clusters where they were supported at a district level and 
were active in routine maternity care provision (Ndola and 
Cap Haitien). Clusters crossed over from control to the 
CRADLE intervention in one of nine steps at 2-monthly 
intervals, with CRADLE devices replacing existing 
equipment at the randomly allocated timepoint. Ethics 
approval was granted by the King’s College London (UK) 
Research Ethics Subcommittee (LRS-14/15-1484) and in 
all countries before the start of the trial (appendix). 
Institutional-level consent on behalf of the clus ter was 
obtained.28  See reference 25 for the protocol.
Participants
All health-care providers working in the cluster facilities 
had access to the intervention. All women identified as 
pregnant or within 42 days of delivery, presenting for 
maternity care in a cluster facility or to community 
health-care providers, were exposed to the intervention. 
There were no exclusion criteria.
Randomisation and masking
The unit of randomisation was the cluster. A restricted 
method of randomisation was used such that there was 
zero rank correlation between events per month and order 
of randomisation to minimise imbalance between inter-
vention and pre-intervention periods due to anticipated 
variation in the primary event rate between clusters. 
A computer-generated randomly allocated sequence run by 
the CRADLE statistician (PTS) determined the order in 
which the clusters received the intervention. All clusters 
were masked to the order until 2 months before receiving 
the intervention, when the next cluster to receive the 
intervention was informed. Because of the nature of the 
intervention, this trial was not masked. The two smallest 
clusters were randomised at the same time. Data were 
gathered monthly, with 20 time periods of 1 month.
Procedures
Before the intervention, various medical devices (where 
previously available) were used in routine maternity 
care, with management by local guidelines (pre-
intervention period). The CRADLE VSA and training 
package was iteratively developed and piloted as 
previously described.25 At the randomly allocated 
timepoint, the training package was delivered in 
interactive group sessions to health-care providers from 
each of the clinical areas in the cluster facilities. Some 
health-care providers in each cluster became CRADLE 
Champions and provided ongoing training and support 
in their clinical areas. The local implementation 
team provided regular support to all facilities, with at 
least monthly contact. Existing equip ment for mea-
suring vital signs was usually removed from clinical 
use unless specific functions were needed (eg, repeated 
automated measures in a high-dependency unit). We 
did not include a transition period; outcomes occurring 
after implementation start were allocated to the inter-
vention group (post-intervention period). After the end 
of the trial, clusters were able to continue using the 
intervention.
Each cluster included primary (first point of access), 
secondary (first referral point), and tertiary facilities 
(specialty referral facility). Maternity unit staffing levels 
(doctors, nurses, midwives, clinical officers, and com-
munity health-care providers in Ndola and Cap Haitien, 
where active in routine care) and availability of key 
resources (magnesium sulphate, intensive care unit 
beds, and capacity for blood transfusion) were recorded 
throughout the trial period. Major changes to infrastruc-
ture, patient payment requirements, or environmental 
conditions were systematically evaluated each month 
in each site. Service impact was assessed by the pro-
portion of women referred from peripheral facilities to 
higher-level care (collected for a 4-week period before and 
3 months after implementation).
Before the start of the trial, data collection methods 
were optimised based on existing resources available in 
each site. Outcomes were triangulated across multiple 
sources (including referral registers, ward registers, 
patient records, local mortality and morbidity records, 
Figure 1: Thresholds that trigger the traffic light early warning system on the CRADLE Vital Sign Alert
HR=heart rate. sBP=systolic blood pressure.
Blood pressure threshold
(mm Hg)
Display
Red light and up arrow≥160 systolic or 110 diastolic
Yellow light and up arrow140–159 systolic or 90–109 diastolic
Green light
Yellow light and down arrow
Green light
<140 systolic and <90 diastolic
Shock index threshold (HR/sBP)
Red light and down arrow≥1·7
0·9 to <1·7
<0·9
See Online for appendix
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and active case finding) to ensure data completeness. 
Source data consistency and quality were monitored by 
the local research team, with a proportion verified by the 
UK research team. There were no formal stopping rules. 
The trial ended after 20 months as planned.
Outcomes
The primary outcome was a rate of a composite of maternal 
mortality or major morbidity: at least one of maternal 
death (all-cause mortality), eclampsia (occurrence of 
generalised convulsions with increased blood pressure in 
the absence of epilepsy or another condition predisposing 
to convulsions), or emergency hysterectomy (surgical 
removal of all or part of the uterus) per 10 000 deliveries 
per month, occurring during pregnancy, labour, or within 
42 days of delivery. Predefined secondary maternal 
outcomes were the individual components of the primary 
outcome (eclampsia, emergency hysterectomy, and ma-
ternal death), intensive care unit admission (defined as 
admission or referral to a specific intensive care unit or 
equivalent defined highest-level care environment), and 
stroke. Secondary perinatal outcomes, collected per 
1000 women with a primary outcome, were the rate of 
stillbirths and neonatal deaths. Neonatal death was defined 
as death of a live born infant within 28 days of delivery at or 
after 28 weeks of gestation. Stillbirth was defined as born 
without signs of life at or after 28 weeks of gestation. 
Because the intervention itself was not considered likely to 
lead to adverse events, and all major adverse pregnancy 
complications were included as outcomes, no additional 
adverse event reporting was undertaken. There were no 
changes to prespecified outcomes during recruitment, and 
only prespecified analyses were undertaken.
Statistical analysis
Sample size estimation was informed by data from the 
feasibility phase and carried out using Hemming and 
Girling’s methods.29 Assuming 4000 deliveries per cluster 
per month, with nine clusters, each observed for 
20 months, and a baseline event rate of 1% with a 
reduction to 0·75% post-intervention, 2450 outcome 
events were required to have power of 95% (selected 
to account for cluster variability in a stepped-wedge 
randomised controlled trial). A coefficient of variation 
of 0·4 (judged to be high, but plausible, based on our 
pilot data) and an intracluster correlation coefficient 
calculated as 0·0085 were selected for this study design.
We did the planned comparison using risk ratios, but 
it did not converge for the majority of results. This 
finding is common in analyses of rates; therefore, results 
are reported as odds ratios (ORs) with 95% CIs. We used 
logistic regression with generalised estimating equations 
and a population-averaged model for the main analysis.30 
For the primary analysis of the primary outcome and its 
individual components,31 we adjusted for three predictors: 
cluster (categorical), time from start of study (continuous; 
with an interaction between cluster and time so that 
each cluster had its own underlying time trend), and 
total time on the randomised intervention, with time 
before intervention given as zero (continuous). The 
analysis resulted in separate linear time trends in each 
cluster, as prespecified. The model for intervention 
analysis allowed for separate linear trends in each cluster 
before and after the intervention (or a change in trend at 
the time the intervention was introduced, known as 
linear splines or bent stick). This model was an 
amendment from the planned single linear trend in 
each cluster with a sudden change (or step) at the time of 
the intervention (no change in trend or slope, known as 
trend and step). We selected this alternative model 
because the unexpected variation led to greater instability 
in the analysis. The bent stick model achieved greater 
stability. Both analyses are presented and were adjusted 
for the same predictors. A significance level of 0·05 was 
used for all analyses.
As was prespecified in the protocol, we also analysed the 
results for individual clusters using fixed linear trend and 
a step at the start of intervention because bent stick 
models were not reliable for clusters that implemented 
10 clusters assessed for eligibility, comprising 286 facilities
10 clusters randomised, comprising
 232 primary facilities
 44 secondary facilities
 10 tertiary facilities
10 clusters analysed
247 238 pre-intervention deliveries
Freetown, 
Sierra Leone
Kampala, 
Uganda
Ndola, 
Zambia
Lusaka, 
Zambia
Cap Haitien, Haiti,
and Gokak, India
Addis Ababa, 
Ethiopia
Mbale, 
Uganda
Zomba*, 
Malawi
April 1 to 
May 31, 
2016
June 1 to 
July 31, 
2016
Aug 1 to 
Sept 30, 
2016
Oct 1 to 
Nov 30, 
2016
Dec 1,
2016, to 
Jan 31, 
2017
Feb 1 to 
March 31, 
2017
April 1 to 
May 31, 
2017
June 1 to 
July 31, 
2017
Aug 1 to 
Sept 30, 
2017
Oct 1 to
Nov 30, 
2017
288 995 post-intervention deliveries
A
B
Harare, 
Zimbabwe
Pre-intervention Intervention
Figure 2: Trial profile (A) and randomisation schedule (B) 
Data were collected at each randomly allocated timepoint, irrespective of whether the intervention had been 
initiated. Eight primary and eight secondary facilities stopped providing maternity services or closed between the 
start of the trial and analysis. *Plus the Southern Region.
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the intervention early or late and therefore had few data 
points with or without the intervention. Because individual 
patient data were only collected for women with a primary 
outcome, we had to treat all other women as having no 
event and therefore had no information from which to 
estimate the extent of missing data. The possible number 
of women who might have had a primary outcome 
without being recorded was not expected to have changed 
following the intervention.
Sensitivity analysis removing data collected the week 
before and after implementation was originally intended 
to account for the learning phase following introduction 
of the intervention. However, this analysis proved 
impossible because only monthly delivery data could be 
collected. Analysis removing data collected at time 
periods during which there were major external 
influences was done as planned. Autoregressive corre-
lation allows for decreasing cor relations between 
observations over greater time periods; we did further 
analysis for alternative correlation structures as planned 
(appendix). We planned to adjust for any significant 
differences in the characteristics of clusters (number of 
facilities, obstetric resources, and personnel) before and 
after the intervention, but none were found. We calculated 
CIs using generalised estimating equations and robust 
standard errors adjusted for clustering. Statistical 
analyses were done in Stata, version 14.2 (by PTS). This 
study is registered with the ISRCTN registry, number 
ISRCTN41244132.
Role of the funding source
The funders of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to all 
the data in the study and had final responsibility for the 
decision to submit for publication. 
Pre-intervention 
deliveries 
(n=247 238)
Post-intervention 
deliveries 
(n=288 995)
Mean 
throughout trial
Percentage rate of change 
per month (95% CI)
p value Percentage difference 
(95% CI)
p value
Number of deliveries per month 2472 (1569) 2890 (2291) 2681 (1970) 3% (–5 to 11) 0·46 418% (–713 to 1567) 0·49
Place of delivery
Central referral facility 1434 (63·4%) 1282 (55·0%) 1358 (59·2%) 0·1% (–0·3 to 0·4) 0·79 –8·4% (–17·6 to 0·8) 0·11
Peripheral facility 958 (32·8%) 1523 (41·6%) 1241 (37·2%) 0·1% (–0·2 to 0·4) 0·68 8·7% (–0·4 to 17·9) 0·093
Home 105 (4·8%) 118 (4·7%) 111 (4·8%) –0·1% (0·3 to 0·1) 0·28 –0·1% (–2·4 to 2·2) 0·92
Mode of delivery
Caesarean section 366 (16·8%) 494 (18·1%) 430 (17·4%) 0·3% (–0·1 to 0·6) 0·19 1·3% (–2·4 to 5·0) 0·52
Total number of facilities*
Number of primary level care facilities 232 224 228 0 (no trend) ·· –1·0% (–8·0 to 7·0) 0·85
Number of secondary level care facilities 44 36 40 0 (no trend) ·· 1·0% (–2·0 to 1·0) 0·44
Number of tertiary level care facilities 10 10 10 0 (no trend) ·· 0 (no trend) ··
Total number of facilities (per 1000 deliveries)
Number of primary level care facilities 13·8 (15·3) 14·3 (15·7) 14·1 (15·5) 0·0% (–0·4 to 0·4) 0·96 0·4% (–3·9 to 4·7) 0·85
Number of secondary level care facilities 2·8 (5·4) 2·5 (5·5) 2·6 (5·5) 0·0% (–0·1 to 0·1) 0·97 –0·3% (–1·9 to 1·2) 0·66
Number of tertiary level care facilities 0·8 (1·4) 0·8 (1·2) 0·8 (1·3) –0·0%† (–0·0 to 0·0) 0·74 0·0% (–0·3 to 0·4) 0·89
Obstetric resources
Capacity for blood transfusion, mean 
percentage of facilities (SD)
28·9% (21·7) 21·3% (16·4) 25·1% (19·5) –0·1% (–0·3 to 0·1) 0·42 –7·7% (–22·4 to 7·1) 0·34
Adult intensive care unit beds‡ 11·7 (9·1) 10·1 (9·1) 10·9 (9·1) –0·1% (–0·2 to 0·1) 0·35 –1·6% (–6·0 to 2·8) 0·49
Magnesium sulphate available, mean 
percentage of facilities (SD)
76·2% (25·2) 73·1% (23·7) 74·7% (24·5) 0·2% (–0·1 to 0·6) 0·21 –3·0% (–16·2 to 10·1) 0·66
Personnel (per 1000 deliveries)
Total doctors in maternity units 40·0 (33·4) 38·4 (28·7) 39·2 (31·1) 0·0% (–0·3 to 0·4) 0·86 –1·6% (–13·7 to 10·5) 0·80
Obstetricians or gynaecologists 8·9 (8·3) 9·3 (7·6) 9·1 (8·0) 0·0% (–0·1 to 0·1) 0·82 0·4% (–2·4 to 3·3) 0·78
Clinical officers 30·5 (34·3) 20·8 (23·0) 25·6 (29·5) –0·0%† (–0·2 to 0·1) 0·61 –9·5% (–26·6 to 7·4) 0·30
Anaesthetists (doctors) 10·0 (11·1) 6·9 (9.8) 8·5 (10·5) 0·1% (–0·0 to 0·1) 0·17 –3·1% (–9·5 to 3·2) 0·36
Staff members trained as anaesthetists 
available 24 h
4·0 (3·3) 5·7 (4·7) 4·9 (4·2) –0·0%† (–0·1 to 0·0) 0·42 1·7% (–1·4 to 4·9) 0·31
Midwives 67·2 (57·4) 53·7 (41·6) 60·4 (50·5) 0·3% (0·03 to 0·6) 0·056 –13·5% (–48·8 to 21·7) 0·47
Nurses with midwifery training 77·0 (45·9) 104·6 (86·2) 90·8 (70·3) –0·5% (–1·8 to 0·9) 0·51 27·6% (–29.7 to 85·0) 0·37
Data are mean (SD) or n (%) unless otherwise stated. *Primary level care is defined as the first point of access (eg, district clinic, clinic, or rural health post). Secondary level care is defined as a first referral point 
(eg, regional hospital). Tertiary level care is defined as the specialty referral centre (eg, national hospital). †Negative values between 0·00 and –0·05. ‡Adult intensive care unit is defined as a separate ward or 
room offering a higher level of care than the main ward.  
Table 1: Characteristics of all clusters, including month-by-month variation throughout the course of the study
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Results
We approached and included ten clusters, which 
comprised 286 facilities (figure 2). Clusters were well 
balanced in both groups, with no significant differences 
in their characteristics, including mean number of 
deliveries per cluster per month; table 1).
Between April 1, 2016, and Nov 30, 2017, 4067 women 
had a primary outcome (one or more of maternal death 
[n=998], eclampsia [n=2692], and hysterectomy [n=681]) 
from 536 223 deliveries (table 2). There was an 8% re-
duction in the primary outcome in the intervention 
period compared with the pre-intervention period 
(79·4 per 10 000 deliveries pre-intervention to 72·8 per 
10 000 deliveries post-intervention; OR 0·92, 95% CI 
0·86–0·97; p=0·0056; table 2). However, after pre-
specified adjustments (primary analysis) for variation 
between and within clusters over time, no significant 
benefit or harm could be attributed to the intervention 
(OR 1·22, 95% CI 0·73–2·06; p=0·45; table 2). The 
calculated intracluster correlation coefficient was 0·61, 
much higher than the assumed 0·0085.
Analysis was undertaken using alternative correlation 
structures as planned, with no significant findings 
(appendix p 6). Prespecified sensitivity analysis removing 
four periods of data during which there were external 
changes within the site (strike action affecting staffing 
levels in three sites and natural disaster in Haiti) had no 
impact on the results.
A prespecified analysis of the individual components 
of the primary outcome found a significant reduction in 
the rate of emergency hysterectomy in the intervention 
period compared with the pre-intervention period 
(table 2), but the eclampsia and maternal death rates did 
not significantly change (table 2). Very few women had a 
stroke, with 13 in the pre-intervention period and nine 
in the intervention period (convergence for comparison 
not achieved). There was no significant change in the 
number of women admitted to intensive care (table 3).
In delivery data available for 3715 women with a 
primary outcome (including 123 twin and two triplet 
pregnancies), there were 843 (22·7%) stillbirths, with no 
significant difference between groups (table 2).
Nearly all maternal deaths (950 [95·2%] of 997) 
occurred in central referral facilities (table 3). There 
were no sig nificant changes in the cause of maternal 
death between groups (table 3). The highest proportion 
of first eclamptic fits occurred in the community. After 
adjustments, there were no significant changes between 
groups in the place of first fit. 323 (47·4%) of 681 
emergency hysterectomies were performed for ruptured 
uterus, with 260 (38·2%) for postpartum haemorrhage 
alone. After adjustments, there were no significant 
changes in the cause of hysterectomy between groups 
(table 3).
Individual site analysis is limited because clusters were 
purposely selected and these data are non-randomised. 
Pre-intervention deliveries 
(n=247 238)
Post-intervention deliveries 
(n=288 995)
Unadjusted comparison 
(step)
Planned adjusted 
comparison 
(trend and step)*
Adjusted comparison 
(bent stick)*
n (%) or n/N 
(%)
Rate n (%) or n/N 
(%)
Rate Odds ratio 
(95% CI)
p value Odds ratio 
(95% CI)
p value Odds ratio 
(95% CI)
p value
Primary outcome
Composite (one or more of 
eclampsia, hysterectomy, or 
maternal death)
1963 (0·8%) 79·4 per 
10 000 deliveries
2104 (0·7%) 72·8 per 
10 000 deliveries
0·92 
(0·86–0·97)
0·0056 1·13 
(0·85–1·51)
0·40 1·22 
(0·73–2·06)
0·45
Secondary maternal outcomes
Eclampsia 1314 (0·5%) 53·1 per 
10 000 deliveries
1378 (0·5%) 47·7 per 
10 000 deliveries
0·90 
(0·83–0·97)
0·0048 1·30 
(0·82–2·05)
0·27 1·91 
(0·91–4·03)
0·088
Hysterectomy 316 (0·1%) 12·8 per 
10 000 deliveries
365 (0·1%) 12·6 per 
10 000 deliveries
0·99 
(0·85–1·15)
0·88 0·87 
(0·50–1·52)
0·63 0·21 
(0·07–0·66)
0·0072
Maternal death 451 (0·2%) 18·2 per 
10 000 deliveries
547 (0·2%) 18·9 per 
10 000 deliveries
1·04 
(0·92–1·18)
0·56 0·85 
(0·65–01·10)
0·22 0·80 
(0·30–2·09)
0·64
Stroke 13 (<0·1%) 0·5 per 
10 000 deliveries
9 (<0·1%) 0·3 per 
10 000 deliveries
·· ·· ·· ·· ·· ··
Admission to an intensive 
care unit
365 (0·1%) 14·8 per 
10 000 deliveries
232 (0·1%) 8·0 per 
10 000 deliveries
·· ·· 0·60 
(0·39–0·91)
·· 0·79 
(0·53–1·17)
··
Secondary perinatal outcomes†
Stillbirth 343/1782 
(19·2%)
192 per 
1000 pregnancies
500/1933 
(25·9%)
259 per 
1000 pregnancies
·· ·· 1·02 
(0·61–1·69)
·· 0·95 
(0·87–1·04)
··
Neonatal death 52/1782 
(2·9%)
29 per 
1000 pregnancies
77/1933 
(4·0%)
40 per 
1000 pregnancies
·· ·· ·· ·· ·· ··
*Adjusted for cluster effect, time from start of study (with an interaction between cluster and time so that each cluster had its own underlying time trend), and total time on the randomised intervention. 
†In women with a primary outcome with delivery information. Excludes 17 women with missing delivery information, 45 women who went home after a primary outcome without delivery and were not 
followed up, and 290 women who were less than 28 weeks pregnant at the time of the primary outcome and delivery data were not collected.
Table 2: Primary outcome, and secondary maternal and perinatal outcomes
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However, individual analysis is presented as planned in 
figure 3. The event rate in the pre-intervention period 
ranged from 39·4 per 10 000 de liveries in Lusaka to 
327·6 per 10 000 deliveries in Freetown. After 
adjustment, there was considerable heterogeneity in 
the apparent effect in individual clusters (I²=94·5%), 
with significant benefit shown in three sites, including 
the two clusters with the highest and lowest baseline 
event rate.
Training was delivered to 2747 health-care providers, 
with 3868 devices distributed across 286 facilities. 
On average, 2784 (3·7%) of 74 828 women seen in 
peripheral maternity facilities were referred in the pre-
intervention period compared with 3212 (4·4%) of 
73 371 women in the intervention period (OR 0·89, 
95% CI 0·39–2·05; data from the Mulago cluster are 
excluded because they were not able to collect the 
denominator). However, changes in referral varied 
between sites, with a significant reduction in referral 
rates in five sites, no change in three sites, and a 16-fold 
increase in referrals in a single site (Gokak). This 
increase is thought to be due to the high incidence of 
severe anaemia in Gokak resulting in frequent referrals 
of asymptomatic women due to an elevated shock index 
(this is under further investigation). Overall, there were 
no changes in staffing or resource levels. By the end of 
the trial, 0·6% (n=23) of CRADLE VSAs were reported 
missing and 4·6% (n=180) reported to be broken. The 
most commonly reported reasons were failure of the 
battery, leaking of the valve in the pump, or tears in 
the cuff.
Pre-intervention Post-intervention Planned adjusted 
comparison (trend 
and step)*
Adjusted 
comparison 
(bent stick)*
n/N (%) Rate per 
10 000 deliveries
n/N (%) Rate per 
10 000 deliveries
Place of death (as % of all deaths)
Central referral facility 428/451 (94·9%) ·· 522/546 (95·6%) ·· ·· ··
Peripheral facility 12/451 (2·7%) ·· 17/546 (3·1%) ·· ·· ··
Community 11/451 (2·4%) ·· 7/546 (1·3%) ·· ·· ··
Cause of death
Obstetric haemorrhage 147/451 (32·6%) 6·0 212/546 (38·8%) 7·3 0·86 (0·56–1·33) 0·56 (0·29–1·05)
Pregnancy-related sepsis 67/451 (14·9%) 2·7 74/546 (13·6%) 2·6 ·· ··
Other sepsis 15/451 (3·3%) 0·6 13/546 (2·4%) 0·5 ·· ··
Hypertensive disorder in 
pregnancy (eclampsia, 
pre-eclampsia, or stroke)
81/451 (18·0%) 3·3 123/546 (22·5%) 4·3 0·76 (0·46–1·25) 2·07 (0·33–13·12)
Other 141/451 (31·3%) 5·7 125/546 (22·9%) 4·3 0·88 (0·62–1·24) 0·54 (0·05–5·73)
Place of first eclamptic fit
Central referral facility 506/1314 (38·5%) 20·5 333/1378 (24·2%) 11·5 0·56 (0·33–0·97) 1·17 (0·53–2·55)
Peripheral facility 280/1314 (21·3%) 11·3 363/1378 (26·3%) 12·6 1·55 (1·10–2·20) 1·35 (0·17–10·45)
Community 528/1314 (40·2%) 21·4 682/1378 (49·5%) 23·6 1·02 (0·56–1·86) 2·78 (0·65–11·89)
Cause of hysterectomy
Postpartum haemorrhage 112/316 (35·4%) 4·5 148/365 (40·5%) 5·1 1·23 (0·72–2·10) 0·45 (0·11–1·09)
Ruptured uterus 151/316 (47·8%) 6·1 172/365 (47·1%) 6·0 0·87 (0·41–1·84) 0·12 (0·02–0·82)
Sepsis 21/316 (6·6%) 0·8 25/365 (6·8%) 0·9 ·· ··
Other 32/316 (10·1%) 1·3 20/365 (5·5%) 0·7 ·· ··
Data are n/N (%) or odds ratio (95% CI) unless otherwise stated. *Adjusted for cluster effect, time from start of study (with an interaction between cluster and time so that each 
cluster had its own underlying time trend), and total time on the randomised intervention. 
Table 3: Additional information on primary outcomes
Figure 3: Forest plot of event rates in individual clusters and the effect of the intervention on the primary 
composite outcome analysed with fixed linear trends
Odds ratio
(95% CI)
Intervention period
(event rate per 10 000)
Pre
Addis Ababa
Cap Haitien
Freetown
Gokak
Harare
Lusaka
Mbale
Mulago and Kampala
Ndola
Zomba plus the
Southern Region 
Overall
90·2
82·1
327·6
69·4
95·7
39·4
43·8
73·9
74·3
124·4
89·7
107·7
190·3
37·9
72·8
14·5
40·4
81·2
81·0
183·2
Post
0·87 (0·70–1·09)
0·37 (0·23–0·59)
0·60 (0·50–0·72)
0·84 (0·65–1·08)
0·98 (0·76–1·26)
0·45 (0·33–0·63)
1·28 (1·04–1·57)
1·32 (1·06–1·65)
1·34 (0·98–1·83)
2·09 (1·78–2·47)
1·00·25 2·50·5
Worse with interventionBetter with intervention
79·4 72·8 1·22 (0·73–2·06)
Articles
e354 www.thelancet.com/lancetgh   Vol 7   March 2019
Discussion
This trial was unable to demonstrate a direct effect of the 
CRADLE intervention on a composite outcome of ma-
ternal mortality and morbidity, although together these 
outcomes fell by 8% during the trial. There was con-
siderable heterogeneity of data between and within sites, 
giving insufficient power despite more than 4000 primary 
events, the number of which was higher than anticipated. 
Prespecified secondary analyses showed no significant 
reduction in maternal death or eclampsia but a significant 
reduction in emergency hysterectomy. Further work is 
required to elucidate the importance of this result. It is 
plausible that this reduction represents a true benefit, 
potentially as a result of earlier referral for post-partum 
haemorrhage, as we hypothesised.
The strengths of this study included the randomised 
design in multiple countries, size of the trial population, 
use of routine data triangulated with active case finding, 
implementation into all levels of health-care facilities 
within clusters, and eligibility of all pregnant women. A 
limitation was that imple mentation and data collection 
were by the same team, introducing possible measurement 
bias. It is also plausible that in some clusters, use of the 
intervention might have resulted in increased reporting of 
the primary outcome if previously occurring without 
documentation in the community, with a bias against the 
intervention. However, case finding and data collection 
were carefully optimised in the feasibility phase and closely 
monitored by the local investigator and research team.
The stepped-wedge randomised controlled trial design 
was chosen because phased implementation across 
ten clusters was more feasible than simultaneous imple-
mentation and because it would have been chal lenging to 
achieve sufficient cluster matching. In addition, because 
blood pressure measurement is part of routine maternity 
care and adequate access to equipment in low-resource 
settings is a challenge, delivery to all clusters was deemed 
preferable by our sites. However, this trial design also 
reflects a study limitation because it is vulnerable to tem-
poral trends and external influences, although extensive 
efforts were made to capture and adjust for these factors. 
The decision to involve diverse clusters across eight 
countries was made to enable generalisability. We have 
demonstrated successful intervention delivery in multiple 
settings. Variation between clusters was taken into 
account in the sample size calculation and the randomi-
sation procedure, but there were no reliable data on which 
to adjust for temporal and seasonal trends. These seasonal 
variations were larger than anticipated and, together with 
the size and complexity of the temporal trends, had a 
substantial impact on power, despite the large total 
number of events.
Although stepped-wedge randomised controlled trials 
are becoming increasingly popular,32,33 this trial was 
unusual in being undertaken across multiple countries 
and presents valuable learning for others planning multi-
country stepped-wedge randomised controlled trials. 
We can only identify one published trial undertaken in 
multiple countries (in Europe).34 Compared with parallel-
cluster trial designs, stepped-wedge randomised control-
led trials remain an appropriate solution with an 
intracluster correlation coefficient anticipated to be up 
to 0·1,28 but the potential variation between clusters (and 
logistical challenges) are magnified when the study 
involves multiple countries.
Across all our sites, there was an 8% reduction in the 
primary outcome during the trial period. The statistical 
analysis accounts for event rate trends in each cluster 
before and after the intervention. After adjusting for 
these trends, this reduction cannot be directly attributed 
to the intervention. Trends from WHO indicate that over 
the past 5 years, the mean reduction in maternal 
mortality ratio across the eight countries in this trial was 
only 2% per year (range –1% in Malawi to 22% in 
Ethiopia).1 There is a scarcity of reliable prevalence 
trends for eclampsia and maternal morbidity in these 
countries because data are primarily limited to 
intervention studies or small observational studies. It is 
plausible that the intervention was beneficial but not 
proven by our trial design or that participation in the 
trial and the process of data collection were associated 
with benefit.35
Behavioural change theory states that to be effective, 
interventions should target specific behaviours and that 
success is dependent on having the necessary skill and 
intention, in the absence of environmental constraints.36 
The CRADLE intervention incorporated the device with 
an educational package and clinical champions to 
promote the importance of vital signs measurement in 
pregnancy. We hypothesised that this intervention would 
improve the number of women that receive vital signs 
monitoring and subsequent manage ment of pregnancy 
complications. Following identification of complications, 
prevention of morbidity and mortality is dependent on 
capacity of health-care providers and the health-care 
system to respond. Although desirable, it was not feasible 
to measure individual abnormal vital signs and clinical 
management. Accurate measures of quality of care are 
challenging in low-resource settings and can be associated 
with methodological issues;37,38 therefore, it is a strength 
that important, unequivocal clinical outcomes were 
measured. A mixed-methods process evaluation was 
undertaken in parallel to this trial, which measured 
implementation (fidelity, dose, and reach) and explored 
potential mechanisms of the intervention in each cluster. 
Further analysis of these results, exploring whether these 
measures, in combination with staffing and resource 
levels, affect the effect of the intervention in different 
clusters, will be published.
In conclusion, the CRADLE intervention was success-
fully implemented into routine maternity care in low-
resource settings. The intervention was associated with 
a reduction in a composite of death, eclampsia, and 
hysterectomy but only hysterectomy was directly at tributed 
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to the intervention. The trial had insufficient power 
because of unexpected variation between clusters and 
despite the high number of primary outcome events. 
Potential variation between and within clusters, over time, 
should be taken into consideration in planning future 
stepped-wedge random ised controlled trials. Future 
research could consider a cluster or stepped-wedge 
randomised controlled trial in a single country that should 
use extensive pilot data (including accurate intracluster 
correlation and baseline temporal trends) to inform 
the power calculation. In-depth analysis of clinical care 
pathways in a subset of districts could be considered. 
Effects on individual sites and components of the primary 
outcome in relation to availability of resources and staffing 
need investigation.
Contributors
NV, HLN, PTS, JS, LCC, and AHS contributed to the conception, 
analysis, and interpretation of the work. NV, EL, MFG, and SG 
contributed to the acquisition of data. NV led the literature search and 
writing. PTS led statistical analysis. All authors contributed to  
interpretation of the work, writing of the manuscript, and final approval 
of this version, and agree to be accountable for all aspects of the work.
CRADLE Trial Collaborative Group
Doreen Bukani, Grace Makonyola, Paul Toussaint, Adeline Vixama, 
Grace Greene, Carwyn Hill, Emily Nakirijja, Doreen Birungi, 
Noela Kalyowa, Dorothy Namakula, Josaphat Byamugisha, 
Annettee Nakimuli, Nathan Mackayi Odeke, James Ditai, 
Julius Wandabwa, Fatmata Momodou, Margaret Sesay, Patricia Sandi, 
Jeneba Conteh, Jesse Kamara, Matthew Clarke, Rebecca Best, 
Josephine Miti, Martina Chima, Mercy Kopeka , Bellington Vwalika, 
Christine Jere, Thokozile Musonda, Sebastian Chinkoyo, Violet Mambo, 
Yonas Guchale, Lomi Yadeta, Feiruz Surur, Geetanjali M Mungarwadi, 
Sphoorthi S Mastiholi, Chandrappa C Karadiguddi, Umesh Charantimath, 
Natasha Hezelgrave, Kate E Duhig, Monice Kachinjika, Adrian Brown, 
Mrutyunjaya Bellad, Jane Makwakwa.
Declaration of interests
We declare no competing interests. 
Data sharing
The dataset will be available to appropriate academic parties on request 
from the Chief Investigator in accordance with the data sharing policies 
of King’s College London (UK), with input from the Co-investigator 
group where applicable.
Acknowledgments
The trial was funded by the UK Medical Research Council, Indian 
Department of Biotechnology, and UK Department of International 
Development Global Research Programme (MR/N006240/1). JS and 
PTS are supported by the UK National Institute for Health Research 
(NIHR) Collaboration for Leadership in Applied Health Research and 
Care South London at King’s College Hospital National Health Service 
Foundation Trust. LCC is supported by an NIHR Research Professorship 
(RP-2014-05-019). The views expressed are those of the authors and not 
necessarily those of the National Health Service, the NIHR, or the UK 
Department of Health and Social Care.
References
1 WHO, UNICEF, UNFPA, The World Bank and the United Nations 
Population Division. Trends in maternal mortality: 1990 to 2015. 
Estimates by WHO, UNICEF, UNFPA, The World Bank and the 
United Nations Population Division. Geneva: World Health 
Organization, 2015.
2 Say L, Chou D, Gemmill A, et al. Global causes of maternal death: 
a WHO systematic analysis. Lancet Glob Health 2014; 2: e323–33.
3 Campbell OMR, Graham WJ. Strategies for reducing maternal 
mortality: getting on with what works. Lancet 2006; 368: 1284–99.
4 Thaddeus S, Maine D. Too far to walk: maternal mortality in 
context. Soc Sci Med 1994; 38: 1091–110.
5 WHO. The World Health Report 2005: make every mother and 
child count. Geneva: World Health Organization, 2005.
6 Isaacs RA, Wee MY, Bick DE, et al. A national survey of obstetric 
early warning systems in the United Kingdom: five years on. 
Anaesthesia 2014; 69: 687–92.
7 Singh S, McGlennan A, England A, Simons R. A validation study of 
the CEMACH recommended modified early obstetric warning 
system (MEOWS). Anaesthesia 2012; 67: 12–18.
8 Ryan HM, Jones MA, Payne BA, et al. Validating the performance 
of the modified early obstetric warning system multivariable model 
to predict maternal intensive care unit admission. 
J Obstet Gynaecol Can 2017; 39: 728–33.e3.
9 Hedriana HL, Wiesner S, Downs BG, Pelletreau B, Shields LE. 
Baseline assessment of a hospital-specific early warning trigger 
system for reducing maternal morbidity. Int J Gynaecol Obstet 2016; 
132: 337–41.
10 Carle C, Alexander P, Columb M, Johal J. Design and internal 
validation of an obstetric early warning score: secondary analysis of 
the Intensive Care National Audit and Research Centre Case Mix 
Programme database. Anaesthesia 2013; 68: 354–67.
11 Paternina-Caicedo A, Miranda J, Bourjeily G, et al. Performance of 
the Obstetric Early Warning Score in critically ill patients for the 
prediction of maternal death. Am J Obstet Gynecol 2017; 216: 58.e1–8.
12 Lappen JR, Keene M, Lore M, Grobman WA, Gossett DR. 
Existing models fail to predict sepsis in an obstetric population with 
intrauterine infection. Am J Obstet Gynecol 2010; 203: 573.e1–5.
13 Edwards SE, Grobman WA, Lappen JR, et al. Modified obstetric 
early warning scoring systems (MOEWS): validating the diagnostic 
performance for severe sepsis in women with chorioamnionitis. 
Am J Obstet Gynecol 2015; 212: 536.e1–8.
14 Shields LE, Wiesner S, Klein C, Pelletreau B, Hedriana HL. Use of 
Maternal Early Warning Trigger tool reduces maternal morbidity. 
Am J Obstet Gynecol 2016; 214: 527.e1–6.
15 Baker EC, Hezelgrave N, Magesa SM, Edmonds S, de Greeff A, 
Shennan A. Introduction of automated blood pressure devices 
intended for a low resource setting in rural Tanzania. Trop Doct 
2012; 42: 101–03.
16 Betrán AP, Bergel E, Griffin S, et al. Provision of medical supply kits 
to improve quality of antenatal care in Mozambique: a stepped-wedge 
cluster randomised trial. Lancet Glob Health 2018; 6: e57–65.
17 WHO. World Health Report 2006: working together for health. 
Geneva: World Health Organization, 2006.
18 Boene H, Vidler M, Augusto O, et al. Community health worker 
knowledge and management of pre-eclampsia in southern 
Mozambique. Reprod Health 2016; 13 (suppl 2): 105.
19 de Greeff A, Nathan H, Stafford N, Liu B, Shennan AH. 
Development of an accurate oscillometric blood pressure device for 
low resource settings. Blood Press Monit 2008; 13: 342–48.
20 Nathan HL, de Greeff A, Hezelgrave NL, Chappell LC, 
Shennan AH. An accurate semiautomated oscillometric blood 
pressure device for use in pregnancy (including pre-eclampsia) in a 
low-income and middle-income country population: the Microlife 
3AS1-2. Blood Press Monit 2015; 20: 52–55.
21 Nathan HL, de Greeff A, Hezelgrave NL, Chappell LC, 
Shennan AH. Accuracy validation of the Microlife 3AS1-2 blood 
pressure device in a pregnant population with low blood pressure. 
Blood Press Monit 2015; 20: 299–302.
22 Nathan HL, Vousden N, Lawley E, et al. Development and 
evaluation of a novel Vital Signs Alert device for use in pregnancy in 
low-resource settings. BMJ Innov 2018; 4: 192–98.
23 Nathan HL, Boene H, Munguambe K, et al. The CRADLE vital 
signs alert: qualitative evaluation of a novel device designed for use 
in pregnancy by healthcare workers in low-resource settings. 
Reprod Health 2018; 15: 5.
24 Schneider H, Okello D, Lehmann U. The global pendulum swing 
towards community health workers in low- and middle-income 
countries: a scoping review of trends, geographical distribution and 
programmatic orientations, 2005 to 2014. Hum Resour Health 2016; 
14: 65.
25 Nathan HL, Duhig K, Vousden N, et al. Evaluation of a novel device 
for the management of high blood pressure and shock in pregnancy 
in low-resource settings: study protocol for a stepped-wedge 
cluster-randomised controlled trial (CRADLE-3 trial). Trials 2018; 
19: 206.
Articles
e356 www.thelancet.com/lancetgh   Vol 7   March 2019
26 Vousden N, Lawley E, Nathan HL, et al. Evaluation of a novel vital 
sign device to reduce maternal mortality and morbidity in 
low-resource settings: a mixed method feasibility study for the 
CRADLE-3 trial. BMC Pregnancy Childbirth 2018; 18: 115.
27 Moore GF, Audrey S, Barker M, et al. Process evaluation of complex 
interventions: Medical Research Council guidance. BMJ 2015; 
350: h1258.
28 Hemming K, Haines TP, Chilton PJ, Girling AJ, Lilford RJ. 
The stepped wedge cluster randomised trial: rationale, design, 
analysis, and reporting. BMJ 2015; 350: h391.
29 Hemming K GA. A menu-driven facility for power and 
detectable-difference calculations in stepped-wedge 
cluster-randomized trials. Stata J 2014; 14: 363–80.
30 Hussey MA, Hughes JP. Design and analysis of stepped wedge 
cluster randomized trials. Contemp Clin Trials 2007; 28: 182–91.
31 European Agency for the Evaluation of Medicinal Products. Points 
to consider on multiplicity issues in clinical trials. Sept 19, 2002. 
https://www.ema.europa.eu/documents/scientific-guideline/points-
consider-multiplicity-issues-clinical-trials_en.pdf (accessed 
Jan 12, 2018).
32 Kristunas C, Morris T, Gray L. Unequal cluster sizes in 
stepped-wedge cluster randomised trials: a systematic review. 
BMJ Open 2017; 7: e017151.
33 Martin J, Taljaard M, Girling A, Hemming K. Systematic review finds 
major deficiencies in sample size methodology and reporting for 
stepped-wedge cluster randomised trials. BMJ Open 2016; 6: e010166.
34 van der Kooi T, Sax H, Pittet D, et al. Prevention of hospital 
infections by intervention and training (PROHIBIT): results of a 
pan-European cluster-randomized multicentre study to reduce 
central venous catheter-related bloodstream infections. 
Intensive Care Med 2018; 44: 48–60.
35 McCarney R, Warner J, Iliffe S, van Haselen R, Griffin M, Fisher P. 
The Hawthorne effect: a randomised, controlled trial. 
BMC Med Res Methodol 2007; 7: 30.
36 Fishbein M. The role of theory in HIV prevention. AIDS Care 2000; 
12: 273–78.
37 Pirkle CM, Dumont A, Zunzunegui MV. Criterion-based clinical 
audit to assess quality of obstetrical care in low- and middle-income 
countries: a systematic review. Int J Qual Health Care 2011; 
23: 456–63.
38 Dettrick Z, Firth S, Jimenez Soto E. Do strategies to improve quality 
of maternal and child health care in lower and middle income 
countries lead to improved outcomes? A review of the evidence. 
PLoS One 2013; 8: e83070.
